Guest guest Posted June 29, 2008 Report Share Posted June 29, 2008 Basel, June 13, 2008 - New data from a large, international clinical trial find that patients with newly diagnosed chronic myeloid leukemia who received Glivec® (imatinib)[*] at 800 mg/day as their initial treatment achieved clinical milestones significantly faster than those receiving the standard 400 mg/day dose. http://www.novartis.com/newsroom/media-releases/en/2008/1227552.shtml Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.